title: Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
authors.forename: M
authors.initials: M
authors.lastname: Athanassiou-Metaxa
authors.forename: V
authors.initials: V
authors.lastname: Tzimouli
authors.forename: M
authors.initials: M
authors.lastname: Economou
authors.forename: A
authors.initials: A
authors.lastname: Taparkou
authors.forename: N
authors.initials: N
authors.lastname: Tourkantoni
authors.forename: F
authors.initials: F
authors.lastname: Kanakoudi-Tsakalidou
mesh_terms: D000293:Adolescent; D000328:Adult; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D016130:Immunophenotyping; D011728:Pyridones / Q000008:administration & dosage / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D002614:Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine